A double-blind, randomised, placebo controlled, proof-of-concept study in subjects with abdominal or thoracic chronic scar pain to assess the analgesic properties of intradermal doses of Dysport® - Dysport in Post-Surgical Neuralgia (RESPITE)

Ipsen Innovation SAS0 个研究点目标入组 16 人开始时间: 2018年8月2日最近更新: 2021年1月5日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 16

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•In order to be considered eligible for enrolment in the study, subjects must fulfil all of the following criteria:
•1)Male and female subjects aged between 18 and 80 years inclusive at the time of giving informed consent.
•2)Subjects suffering from an area of chronic pain post-abdominal or thoracic surgery, chronic abdominal or thoracic scar pain
•3)Longitudinal axis of the pain area of 10 cm long maximum (as mapped upon screening).
•4)Subjects with moderate to severe pain, i.e. spontaneous NRS score of 4-8 stable for the previous month before screening.
•5)Stable use of analgesics (or any medication impacting pain perception) during the month before screening and expected to be stable for the study duration.
•6)Time from surgery which caused the painful scar more than six months and less than five years at screening.
•7)No other distracting pain either chronic or acute.
•8)Female subjects of childbearing potential must have a negative urine pregnancy test result and be willing to use reliable contraceptive measures throughout study participation. Reliable forms of contraception include but are not limited to hormonal contraceptives (e.g. oral, patch, injection), double-barrier (e.g. male condom plus spermicide, or female diaphragm plus spermicide), intrauterine device, male partner has had a vasectomy, total abstinence from intercourse with male partners (periodic abstinence is not acceptable). Female subjects meeting any of the following criteria are not considered to be of childbearing potential: postmenopausal (= 47 years of age and amenorrhoeic for at least 12 consecutive months), have been sterilised surgically (e.g. bilateral tubal ligation), have had a hysterectomy, have had a bilateral oophorectomy.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 0

排除标准

•Subjects who meet any of the following criteria will not be considered eligible for enrolment in the study.
•1)Previous treatment with BTX (any serotype) during the past six months before screening.
•2)History of hypersensitivity to any of the components of the Dysport formulation (which includes human serum albumin and lactose) or allergy to cow's milk protein.
•3)Known hypersensitivity to lidocaine or other anaesthetics of the amide type, known hypersensitivity to hydroxybenzoates, complete heart block, hypovolaemia.
•4)Any medical condition that may put the subject at risk with exposure to BTX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disease that might interfere with neuromuscular function.
•5)Neuroma in the scar pain area, diagnosed per ultrasound.
•6)Use of agents that could interfere with neuromuscular transmission, including calcium channel blockers, penicillamine, aminoglycosides, lincosamides, polymixins, magnesium sulphate, anticholinesterases, succinylcholine and quinidine.
•7)Need of any prohibited medication.
•8)Any abnormal laboratory value, physical examination, vital signs, or electrocardiogram (ECG) that, in the opinion of the investigator, is clinically significant and that would compromise the safety of the subject in the study.
•9)Positive for hepatitis B antigen or hepatitis C virus ribonucleic acid, positive results for human immunodeficiency virus, or who receives diagnosis for acquired immunodeficiency syndrome.
•10)Positive urine screen for drugs of abuse (except for cotinine and unless explained by the investigator for therapeutic use of medication) or any history of drug or alcohol abuse, misuse, physical or psychological dependence, mood changes, sleep disturbance and functional capacity which have an impact on pain perception.
•11)Significant neurological or psychiatric disorders including mental instability (unrelated to the pain) that could interfere with pain assessments; other pre-existing pain syndromes, acute or chronic, that might impair the assessment of the scar pain.
•12)Any medical history of significance and/or inadequately controlled such as cardiovascular (e.g. uncontrolled high blood pressure, high risk of cardiovascular events, severe heart failure), pulmonary (e.g. uncontrolled asthma or emphysema), heamatologic, (e.g. coagulopathy/bleeding disorders), neurological (e.g. swallowing problems, blurred or double vision, trouble saying words clearly (dysarthria), hoarseness or change or loss of voice (dysphonia)), liver disease (e.g. severe hepatic impairment), kidney disease (e.g. impaired renal function in subjects taking diuretics, angiotensin converting enzyme (ACE)-inhibitors, or angiotensin II antagonists), endocrine, immunologic, dermatologic painful conditions or any other conditions that may compromise in the opinion of the investigator the ability of the subject to participate in the study.
•13)If in the investigator’s opinion there are any factors that may confound the analysis of the study regarding efficacy and safety (e.g. an NRS > 9).
•14)The subject’s primary care physician has provided evidence which can be used to confirm that within the last 12 months of dosing that there is nothing in their medical history that would preclude their enrolment into a clinical study.
•15)Previous randomisation in this study.
•16)Subjects who participated in a clinical research study involving a new chemical entity or an experime

研究者

发起方

Ipsen Innovation SAS

相似试验

已完成

不适用

A clinical study to evaluate the efficacy and safety of LibidolynÃ?Â® when compared with placebo in improving sexual health of male subjects.

CTRI/2022/03/041069Herbalyn Lifesciences Inc60

已完成

不适用

This is a study to evaluate the efficacy and safety of SlimilynÃ?Â® Capsules verses placebo in overweight and obese adult subjects.

CTRI/2022/03/040987Herbalyn Lifesciences Inc60

进行中（未招募）

1 期

A double-blind, randomised, placebo controlled, three-period crossover study to investigate the pharmacodynamic effect of two CRF-1 antagonists GSK561679 and GW876008 on meal induced cortisol responses in patients with IBS.Irritable Bowel Syndrome

EUCTR2007-000929-22-IEGlaxoSmithKline R & D Limited

已完成

2 期

A phase 2a proof of concept study to evaluate efficacy and safety of SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus

CTRI/2021/08/035384Sanofi Healthcare India Private Limited5

进行中（未招募）

1 期

Proof of concept study of SAR443122 in patients with cutaneous lupus erythematosusCutaneous Lupus Erythematosus

EUCTR2020-004703-14-HUSanofi-Aventis Recherche & Développement135